Role of erlotinib in the treatment of non-small cell lung cancer: clinical outcomes in wild-type epidermal growth factor receptor patients
B Piperdi, R Perez-Soler - Drugs, 2012 - Springer
Erlotinib is an orally administered small molecule inhibitor of epidermal growth factor
receptor (EGFR) tyrosine kinase. Erlotinib at the standard oral daily dose of 150 mg is …
receptor (EGFR) tyrosine kinase. Erlotinib at the standard oral daily dose of 150 mg is …
Erlotinib after Gefitinib failure in female never-smoker Asian patients with pulmonary adenocarcinoma
The activity of erlotinib after gefitinib failure in non-small cell lung cancer patients with all
four favorable clinical factors including female, never smoker, Asian, and adenocarcinoma …
four favorable clinical factors including female, never smoker, Asian, and adenocarcinoma …
Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non–small-cell lung cancer: a meta-analysis of 13 randomized trials
F Petrelli, K Borgonovo, M Cabiddu, S Barni - Clinical lung cancer, 2012 - Elsevier
Advanced non–small-cell lung cancer (NSCLC) harboring activating mutations of epidermal
growth factor receptor (EGFR) are particularly sensitive to tyrosine kinase inhibitors (TKIs) …
growth factor receptor (EGFR) are particularly sensitive to tyrosine kinase inhibitors (TKIs) …
A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations
H Asahina, K Yamazaki, I Kinoshita, N Sukoh… - British journal of …, 2006 - nature.com
Retrospective analysis has shown that activating mutations in exons 18–21 of the epidermal
growth factor receptor (EGFR) gene are a predictor of response to gefitinib. We conducted a …
growth factor receptor (EGFR) gene are a predictor of response to gefitinib. We conducted a …
[HTML][HTML] A randomized phase 2 study of gefitinib with or without pemetrexed as first-line treatment in nonsquamous NSCLC with EGFR mutation: final overall survival …
JCH Yang, Y Cheng, H Murakami, PC Yang… - Journal of Thoracic …, 2020 - Elsevier
Introduction Clinical studies have shown that a combination of a tyrosine kinase inhibitor
(TKI) and pemetrexed overcame acquired resistance to epidermal growth factor receptor …
(TKI) and pemetrexed overcame acquired resistance to epidermal growth factor receptor …
[HTML][HTML] Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor …
T De Pas, F Toffalorio, M Manzotti, C Fumagalli… - Journal of Thoracic …, 2011 - Elsevier
Introduction Mutations of the epidermal growth factor receptor (EGFR) have been proven to
predict activity of the EGFR-tyrosine kinase inhibitors (EGFR-TKI), gefitinib and erlotinib …
predict activity of the EGFR-tyrosine kinase inhibitors (EGFR-TKI), gefitinib and erlotinib …
Predictive biomarkers to tyrosine kinase inhibitors for the epidermal growth factor receptor in non-small-cell lung cancer
A De Luca, N Normanno - Current Drug Targets, 2010 - ingentaconnect.com
The epidermal growth factor receptor (EGFR) and its ligands are frequently expressed in
non-small-cell lung cancer (NSCLC). The EGFR tyrosine kinase inhibitors (TKIs) erlotinib …
non-small-cell lung cancer (NSCLC). The EGFR tyrosine kinase inhibitors (TKIs) erlotinib …
Pooled analysis of clinical outcome for EGFR TKI‐treated patients with EGFR mutation‐positive NSCLC
Patients with non‐small‐cell lung cancer (NSCLC) appear to gain particular benefit from
treatment with epidermal growth factor receptor (EGFR) tyrosine‐kinase inhibitors (TKI) if …
treatment with epidermal growth factor receptor (EGFR) tyrosine‐kinase inhibitors (TKI) if …
Use of the epidermal growth factor receptor inhibitors gefitinib, erlotinib, afatinib, dacomitinib, and icotinib in the treatment of non-small-cell lung cancer: a systematic …
PM Ellis, N Coakley, R Feld, S Kuruvilla, YC Ung - Current oncology, 2015 - mdpi.com
Introduction: This systematic review addresses the use of epidermal growth factor receptor
(egfr) inhibitors in three populations of advanced non-small-cell lung cancer (nsclc) patients …
(egfr) inhibitors in three populations of advanced non-small-cell lung cancer (nsclc) patients …
The emerging role of epidermal growth factor receptor (EGFR) inhibitors in first-line treatment for patients with advanced non-small cell lung cancer positive for EGFR …
I Okamoto, T Mitsudomi, K Nakagawa… - … advances in medical …, 2010 - journals.sagepub.com
Gefitinib and erlotinib, small-molecule tyrosine kinase inhibitors (TKIs) of the epidermal
growth factor receptor (EGFR), were the first molecularly targeted agents to become …
growth factor receptor (EGFR), were the first molecularly targeted agents to become …